Study Name: Post-Menopausal Symptoms
Clinics: Blackpool, Cannock, Leeds, Liverpool, Manchester, Teesside.
Therapy Area: Post-Menopausal Symptoms
Gender and Age: Females aged 40-65
MAC Clinical Research is currently conducting a trial to test a potential treatment for symptoms in post-menopausal women. Post-menopausal symptoms include hot flushes which are episodes of flushing, sweating, and intense heat sensation. There are few good treatment options currently available. HRT is effective but has many unwelcome side effects. Other treatments are safer but don’t work as well. It has recently been found that hot flushes may be treated by targeting the nerve cells in the brain that trigger the symptoms. These nerve cells have been found to be enlarged in post-menopausal women.
The trial medication is being developed for the treatment of hot flushes and it is hoped that it may provide rapid and long-lasting control of hot flushes and a better general quality-of-life. During the trial, eligible patients will receive either 40mg, 80mg, 120mg or 160mg of the trial medication, or matching placebo. All patients will receive placebo at some time during the trial. When the trial first starts, there will be an 80% chance that a patient will get the trial medication for most of the study. However, this may reduce slightly as the trial progresses. The trial medication or placebo will be taken orally, once daily for 14 weeks of the 19-week trial period and there will be 8 visits in total to one of our clinics.
Reimbursement: Upto £580 for taking part. Reasonable travel expenses will also be reimbursed, or transport can be provided.
Key Inclusion Criteria
Post-menopausal females aged 40-65
Key Exclusion Criteria
Any uncontrolled or unstable medical condition, including uncontrolled high blood pressure
Unwilling to stop use of any hormonal therapy for the duration of the trial
Other eligibility criteria will apply. Please contact MAC for more information.
Any other information
Eligible patients will receive a health screen and study participation will be in collaboration with the patient’s treating physician.